Growth Hormone Action as a Target in Cancer: Significance, Mechanisms, and Possible Therapies
Endocrine Reviews · 2025
DOI: 10.1210/endrev/bnae030 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Endocrine Reviews, 2025. Verfasst von Reetobrata Basu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Edison Biotechnology Institute, Ohio University, Athens, OH 45701, USA. Hauptthemen laut MEDLINE: Neoplasms, Human Growth Hormone, Growth Hormone. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 727 Literaturangaben. Gefördert von: NIA NIH HHS.
Abstract (Originalsprache)
Growth hormone (GH) is a pituitary-derived endocrine hormone required for normal postnatal growth and development. Hypo- or hypersecretion of endocrine GH results in 2 pathologic conditions, namely GH deficiency (GHD) and acromegaly. Additionally, GH is also produced in nonpituitary and tumoral tissues, where it acts rather as a cellular growth factor with an autocrine/paracrine mode of action. An increasingly persuasive and large body of evidence over the last 70 years concurs that GH action is implicit in escalating several cancer-associated events, locally and systemically. This pleiotropy of GH's effects is puzzling, but the association with cancer risk automatically raises a concern for patients with acromegaly and for individuals treated with GH. By careful assessment of the available knowledge on the fundamental concepts of cancer, suggestions from epidemiological and clinical studies, and the evidence from specific reports, in this review we aimed to help clarify the distinction of endocrine vs autocrine/paracrine GH in promoting cancer and to reconcile the discrepancies between experimental and clinical data. Along this discourse, we critically weigh the targetability of GH action in cancer—first by detailing the molecular mechanisms which posit GH as a critical node in tumor circuitry; and second, by enumerating the currently available therapeutic options targeting GH action. On the basis of our discussion, we infer that a targeted intervention on GH action in the appropriate patient population can benefit a sizable subset of current cancer prognoses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Edison Biotechnology Institute, Ohio University, Athens, OH 45701, USA.
- Department of Biomedical Sciences, Ohio University Heritage College of Osteopathic Medicine (OU-HCOM), Athens, OH 45701, USA.
- Diabetes Institute, Ohio University Heritage College of Osteopathic Medicine (OU-HCOM), Athens, OH 45701, USA.
- SEMPR, Endocrine Division, Department of Internal Medicine, Federal University of Parana, Curitiba 80060-900, Brazil.
- Molecular and Cellular Biology Program, Ohio University, Athens, OH 45701, USA.
ORCID-Profile: Reetobrata Basu, John J Kopchick
Förderung
- NIA NIH HHS
Zitieren
APA
Basu, R., Boguszewski, C. L., & Kopchick, J. J. (2025). Growth Hormone Action as a Target in Cancer: Significance, Mechanisms, and Possible Therapies. Endocrine Reviews. https://doi.org/10.1210/endrev/bnae030
Vancouver
Basu R, Boguszewski CL, Kopchick JJ. Growth Hormone Action as a Target in Cancer: Significance, Mechanisms, and Possible Therapies. Endocrine Reviews. 2025. doi:10.1210/endrev/bnae030
BibTeX
@article{Basu2025,
author = {Basu, Reetobrata and Boguszewski, Cesar L and Kopchick, John J},
title = {Growth Hormone Action as a Target in Cancer: Significance, Mechanisms, and Possible Therapies},
journal = {Endocrine Reviews},
year = {2025},
doi = {10.1210/endrev/bnae030}
}
EUVIMED